Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells

被引：408

作者：

Jin, Liqing ^{[2
]}

Lee, Erwin M. ^{[1
]}

Ramshaw, Hayley S. ^{[3
]}

Busfield, Samantha J. ^{[4
]}

Peoppl, Armando G. ^{[2
]}

Wilkinson, Lucy ^{[5
]}

Guthridge, Mark A. ^{[3
]}

Thomas, Daniel ^{[3
]}

Barry, Emma F. ^{[3
]}

Boyd, Andrew ^{[5
]}

Gearing, David P. ^{[4
]}

Vairo, Gino ^{[4
]}

Lopez, Angel F. ^{[3
]}

Dick, John E. ^{[2
]}

Lock, Richard B. ^{[1
]}

机构：

[1] Univ New S Wales, Childrens Canc Inst Australia Med Res, Sydney, NSW 2031, Australia

[2] Univ Hlth Network, Div Cell & Mol Biol, Toronto, ON M5G 1L7, Canada

[3] Inst Med & Vet Sci, Div Human Immunol, Ctr Canc Biol, Adelaide, SA 5000, Australia

[4] CSL Ltd, Melbourne, Vic 3052, Australia

[5] Queensland Inst Med Res, Brisbane, Qld 4029, Australia

来源：

CELL STEM CELL | 2009年 / 5卷 / 01期

关键词：

ACUTE MYELOGENOUS LEUKEMIA; COLONY-STIMULATING FACTOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; INTERLEUKIN-3; RECEPTOR; HEMATOPOIETIC-CELL; BONE-MARROW; SHORT-TERM; G-CSF; INTRAFEMORAL TRANSPLANTATION; GROWTH-FACTORS;

D O I：

10.1016/j.stem.2009.04.018

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

Leukemia stem cells (LSCs) initiate and sustain the acute myeloid leukemia (AML) clonal hierarchy and possess biological properties rendering them resistant to conventional chemotherapy. The poor survival of AML patients raises expectations that LSC-targeted therapies might achieve durable remissions. We report that an anti-interleukin-3 (IL-3) receptor a chain (CD123)-neutralizing antibody (7133) targeted AML-LSCs, impairing homing to bone marrow (BM) and activating innate immunity of nonobese diabetic/severe-combined immunodeficient (NOD/SCID) mice. 7133 treatment profoundly reduced AML-LSC engraftment and improved mouse survival. Mice with preestablished disease showed reduced AML burden in the BM and periphery and impaired secondary transplantation upon treatment, establishing that AML-LSCs were directly targeted. 7133 inhibited IL-3-mediated intracellular signaling of isolated AML CD34(+) CD38(-) cells in vitro and reduced their survival. These results provide clear validation for therapeutic monoclonal antibody (mAb) targeting of AML-LSCs and for translation of in vivo preclinical research findings toward a clinical application.

引用

页码：31 / 42

页数：12

共 53 条

[31]

MIYAJIMA A, 1993, BLOOD, V82, P1960

[32]

MIYAUCHI J, 1987, BLOOD, V70, P657

[33] Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias [J].

Morgan, MA ;

Reuter, CWM .

ANNALS OF HEMATOLOGY, 2006, 85 (03) :139-163

[34]

Muñoz L, 2001, HAEMATOLOGICA, V86, P1261

[35] Hematopoiesis in mice lacking the entire granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 functions [J].

Nishinakamura, R ;

Miyajima, A ;

Mee, PJ ;

Tybulewicz, VLJ ;

Murray, R .

BLOOD, 1996, 88 (07) :2458-2464

[36] Relations between IL3-induced proliferation and in vitro cytokine secretion of bone marrow cells from AML patients [J].

Nowak, R ;

Oelschlägel, U ;

Gurth, H ;

Range, U ;

Albrecht, S ;

Krebs, U ;

Hietschold, V ;

Ehninger, G .

CYTOKINE, 1999, 11 (06) :435-442

[37] AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML [J].

Pearce, DJ ;

Taussig, D ;

Zilbara, K ;

Smith, LL ;

Ridler, CM ;

Preudhomme, C ;

Young, BD ;

Rohatiner, AZ ;

Lister, TA ;

Bonnet, D .

BLOOD, 2006, 107 (03) :1166-1173

[38]

PEBUSQUE MJ, 1989, LEUKEMIA, V3, P200

[39] Immunophenotypic features of acute myeloid leukemias overexpressing the interleukin 3 receptor alpha chain [J].

Riccioni, R ;

Rossini, A ;

Calabrò, L ;

Diverio, D ;

Pasquini, L ;

Lococo, F ;

Peschle, C ;

Testa, U .

LEUKEMIA & LYMPHOMA, 2004, 45 (08) :1511-1517

[40] Chemotherapy and cancer stem cells [J].

Rich, Jeremy N. ;

Bao, Shideng .

CELL STEM CELL, 2007, 1 (04) :353-355

← 1 2 3 4 5 6 →